Phrontline Biopharma develops antibody-drug conjugates for cancer treatment. Its bispecific antibodies and dual-payload platforms aim to deliver cytotoxic medicines more precisely to tumors and address treatment resistance. Lead candidate TJ101 targets EGFR and B7-H3 and is in early clinical development; other programs include dual-payload candidates targeting HER2 and additional tumor antigens. Its research combines antibody engineering, linker-payload design and site-specific conjugation.
